3.59
-0.17(-4.52%)
Currency In USD
| Previous Close | 3.76 |
| Open | 3.68 |
| Day High | 3.68 |
| Day Low | 3.57 |
| 52-Week High | 6.96 |
| 52-Week Low | 2.28 |
| Volume | 74,513 |
| Average Volume | 91,854 |
| Market Cap | 32.25M |
| PE | -0.89 |
| EPS | -4.03 |
| Moving Average 50 Days | 3.47 |
| Moving Average 200 Days | 4.27 |
| Change | -0.17 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $18.41 as of July 12, 2025 at a share price of $3.59. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $16.48 as of July 12, 2025 at a share price of $3.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene’s NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Newsfile
May 07, 2025 12:00 PM GMT
Salt Lake City, Utah--(Newsfile Corp. - May 7, 2025) - Clene Inc. (NASDAQ: CLNN), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.Rob Etherington, P
Clene to Present at the Emerging Growth Conference
GlobeNewswire Inc.
Apr 14, 2025 12:30 PM GMT
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancing therapies